Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH). The compound was originally developed during research exploring neuropeptide signalling and regulatory mechanisms within the central nervous system.

Unlike the parent hormone ACTH, Semax was designed to retain certain biological signalling properties while lacking hormonal activity associated with adrenal stimulation. Because of this, the peptide has been studied in laboratory environments investigating neurotransmitter regulation, neurotrophic signalling pathways, and cognitive-related biological processes.

Researchers continue to examine Semax in studies involving neuropeptide signalling, brain-derived neurotrophic factor (BDNF) regulation, and central nervous system physiology.

Semax: Quick Facts

Chemical Properties & Molecular Data

Semax is a synthetic heptapeptide, meaning it is composed of seven amino acids arranged in a specific sequence derived from ACTH.

The peptide sequence is designed to replicate certain biological signalling characteristics of the original ACTH fragment while altering its physiological activity.

Peptides derived from neurohormone fragments are commonly studied in research environments investigating neurotransmitter regulation and neurotrophic signalling mechanisms.

Because neuropeptides can influence communication between neurons, compounds such as Semax are frequently investigated in studies exploring brain signalling pathways and molecular neurobiology.

Mechanism of Action

In laboratory research, Semax is studied for its interaction with several neurobiological signalling pathways.

Research suggests the peptide may influence:

• brain-derived neurotrophic factor (BDNF) signalling
• neurotransmitter regulation pathways
• dopaminergic and serotonergic signalling
• neuropeptide receptor activity

These pathways play important roles in neuronal communication and cellular signalling processes within the central nervous system.

Studies have suggested that Semax may influence gene expression related to neurotrophic signalling mechanisms².

Areas of Scientific Research

Semax has been studied in several areas of neurobiology and peptide research.

Common research topics include:

• neurotrophic signalling pathways
  
• cognitive and neurological research
• neurotransmitter regulation
• neuropeptide receptor interaction studies
• central nervous system signalling mechanisms

These research areas aim to better understand how neuropeptides influence brain signalling and neuronal communication.

Reconstitution of Semax

In research environments, Semax is commonly supplied as a lyophilised peptide powder to preserve stability during storage and transport.

Before use in laboratory experiments, the peptide must be reconstituted into solution using a sterile solvent appropriate for research purposes. Solvents such as bacteriostatic water or sterile laboratory water are commonly used.

The solvent is typically added slowly along the inner wall of the vial to allow the peptide powder to dissolve gradually. Gentle swirling may assist dissolution, while vigorous shaking is usually avoided to maintain peptide stability.

Researchers often determine the desired solution concentration before preparing peptide solutions. You can use our Peptide Calculator to estimate dilution ratios and final concentrations based on vial strength and solvent volume.

Storage of Semax

Proper storage conditions are important for maintaining the stability and structural integrity of research peptides.

Lyophilised Semax is typically stored in cool, dry laboratory conditions, often under refrigeration or freezing temperatures to preserve long-term stability.

Protecting peptide samples from moisture, light exposure, and temperature fluctuations helps minimise degradation.

After reconstitution, peptide solutions are usually stored at lower temperatures and handled according to standard laboratory practices to maintain stability during research studies.

References

1. Ashmarin, I.P., et al. (1997). Semax: a new peptide drug with neurotropic and nootropic properties.
   
2. Volkova, A., et al. (2016). Effects of Semax on BDNF expression and neurotrophic signalling pathways.
   
3. Dolotov, O., et al. (2014). Semax regulation of gene expression in the central nervous system.